KLRS · Kalaris Therapeutics Inc
United States · RS rating 3 · As of 2026-10-14
| Price | 2.13 USD |
|---|---|
| 1-day change | -4.5% |
| RS rating (overall / 1M / 3M / 12M) | 3 / 5 / 4 / 12 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 19 / 3 / 30 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -4.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +80.6% |
| Market cap (USD) | $139.9M |